First patch for Alzheimer's dementia

Novartis has launched Exelon transdermal patch (rivastigmine) - the first patch licensed for the symptomatic treatment of mild to moderately severe Alzheimer's dementia.

The six-month international IDEAL (Investigation of transDermal Exelon in ALzheimer’s disease) trial, involving 1,195 patients with Alzheimer’s disease, showed that the Exelon patch demonstrated significant improvements across a range of symptoms including memory and ability to perform everyday activities, compared with placebo. 

The 9.5mg/24hr patch provided similar efficacy to the highest doses of rivastigmine capsules (12mg/day) with a superior tolerability profile. Over 70 per cent of caregivers preferred the patch formulation to oral medication with respect to overall ease of use.

The patches are available in two strengths: 4.6mg/24hr and 9.5mg/24hr. The initial dose is one 4.6mg/24hr patch. After a minimum of four weeks and if well tolerated, this should be increased to the recommended effective dose of 9.5mg/24hr.


Further information: Novartis 01276 692255

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more